One of the [music] things that fascinates me the most is well the human brain. But what is even more fascinating is the fact that the very same biological principles that we our brains use to make sense of our world are the ones that lead us in change. Change in our teams, change in our institutions.We live in very urgent times. All around us, institutions and leaders are facing unprecedented pressure to transform. Be it a corporation facing digital disruption in times of artificial intelligence or a univer ...

What if I told you that your brain reacts to feedback in exactly the same way that reacts to a threat of a wild animal. Yes. Imagine your your boss calls you and says, "Come from my office. I need to give you feedback from the project that you've participated that you were responsible for." Your brain doesn't see any opportunity for learning.Your brain sees danger, danger in front. I want to go out of that. Today, I'm here to explain to you why that happens.And not only that, to give you a new way of how we ...

AbbVie FY Conference Summary Company Overview - **Company**: AbbVie (NYSE: ABBV) - **Date of Conference**: March 03, 2026 - **Key Management Present**: - Scott Rents, Executive Vice President and CFO - Jeff Stewart, Executive Vice President and Chief Commercial Officer - Roopal Thakkar, Executive Vice President, R&D, and CSO Core Industry Insights - **Immunology Trials**: AbbVie is successfully conducting immunology trials, unlike some competitors facing high placebo rates. The company attributes its success to high efficacy levels of its assets, such as HUMIRA, SKYRIZI, and RINVOQ [2][3] - **Clinical Trial Strategy**: AbbVie employs rigorous patient and endpoint selection, real-time data monitoring, and training for trial sites to ensure successful outcomes [4][5][6] Key Product Developments - **RINVOQ**: Demonstrated a doubling of response rates compared to HUMIRA in rheumatoid arthritis trials, indicating strong efficacy [5] - **SKYRIZI**: New subcutaneous induction trial for Crohn's disease showed higher efficacy than the IV version, with a 60% endoscopic response in treatment-naive patients [6] - **Lutikizumab**: Undergoing phase 3 trials for hidradenitis suppurativa (HS) with a focus on stringent endpoints to control placebo responses [7][9] Market Potential - **Hidradenitis Suppurativa**: Identified as an under-penetrated market with significant growth potential, similar to inflammatory bowel disease (IBD) [13] - **Long-term Growth Outlook**: AbbVie projects a high single-digit CAGR from 2024 to 2029, with continued EPS expansion and a strong pipeline in immunology, oncology, and neuroscience [25][26] Pipeline and Future Strategies - **Immunology Pipeline**: Focus on B-cell depletion strategies and combination therapies to reset the standard of care in rheumatologic diseases [30][32] - **Neuroscience**: Anticipation of tavapadone approval, which is expected to complement existing therapies and capture significant market share [41] - **Oncology**: Development of antibody-drug conjugates (ADCs) for various cancers, with promising data from ongoing trials [34][38] Financial Outlook - **Investment in R&D**: AbbVie has increased R&D spending significantly, with plans to continue investing in pipeline development [26][28] - **BOTOX**: Continues to be a major asset with a strong market presence, particularly in aesthetics and therapeutics [50] Additional Insights - **Regulatory Strategy**: AbbVie is adapting to new trial policies to enhance efficiency and speed in clinical studies [14] - **Market Positioning**: The company is well-positioned to capitalize on its diverse portfolio and emerging therapies, with a focus on maintaining a competitive edge in the market [52][53] This summary encapsulates the key points discussed during the AbbVie FY Conference, highlighting the company's strategic focus, product developments, and market outlook.

Core Insights - Johnson & Johnson (JNJ) is a significant player in the oncology segment, contributing approximately 27% to total revenues and 42% to the Innovative Medicine segment sales [1] - The company is also strengthening its presence in immunology and neuroscience, which are becoming key contributors to revenue growth outside of oncology [1] Immunology Segment - Sales in the Immunology segment declined by around 12% in 2025 due to the loss of exclusivity of Stelara, which saw a 42% drop in sales [3][8] - Tremfya, another key immunology drug, is partially offsetting this decline, with sales increasing by 41% in 2025, surpassing $5 billion for the first time [3][8] - J&J expects Tremfya to exceed $10 billion in peak-year sales, while Simponi/Simponi Aria sales rose by 22% to $2.7 billion [3][8] - New products and pipeline candidates, such as Imaavy (approved for generalized myasthenia gravis) and Icotyde/icotrokinra (pending approval for plaque psoriasis), are expected to drive long-term growth [4][5] Neuroscience Segment - The Neuroscience segment saw a 10% increase in sales in 2025, driven by new products like Caplyta and Spravato [6][8] - Caplyta generated $700 million in sales, while Spravato recorded $1.7 billion, reflecting a 57% year-over-year increase [6][7][8] - Both Caplyta and other pipeline candidates have the potential to achieve peak sales of $5 billion [7] Overall Growth Strategy - Despite the near-term headwind from Stelara's loss of exclusivity, J&J's expanding immunology portfolio and fast-growing neuroscience franchise are helping to rebalance its growth mix [8][9] - The company is well-positioned for long-term growth with multiple late-stage pipeline candidates in both immunology and neuroscience [9] Competitive Landscape - Key competitors in the immunology space include AbbVie, Eli Lilly, Amgen, Sanofi, and Pfizer [10] - In the neuroscience sector, significant competitors are Biogen, Lilly, and Pfizer [10]

Core Insights - Neuronetics, Inc. plans to release its fourth quarter 2025 financial and operating results on March 17, 2026, prior to market opening [1] - A conference call to discuss the results will take place at 8:30 a.m. Eastern Time on the same day [2] Company Overview - Neuronetics is a commercial stage medical technology and healthcare company focused on transforming patient lives through neurohealth therapies [1][3] - The company offers NeuroStar Advanced Therapy, a non-drug, noninvasive treatment for patients with major depressive disorder (MDD) and other mental health conditions [3][4] - Neuronetics operates Greenbrook treatment centers across the U.S., providing various treatment modalities including NeuroStar Therapy and SPRAVATO [3] Treatment Indications - NeuroStar Therapy is indicated for treating depressive episodes and reducing anxiety symptoms in adult patients with MDD who have not responded satisfactorily to previous antidepressant treatments [4] - The therapy is also FDA-cleared as an adjunct treatment for adults with obsessive-compulsive disorder and for adolescents aged 15 to 21 with MDD [4]

I'm a person who's always been motivated by science and exploring the world around me. I think the the combination of science and exploration began for me when I was about 10 years old and my father gave me a microscope and I proceeded to go out and try to catalog all the microorganisms that I could find uh with the dream that I would [clears throat] discover something that nobody else had ever seen. This dream of discovery has stuck with me for my entire life.[clears throat] When I entered college, I was v ...

NOTE FROM TED: TED does not endorse the use of psychedelics or other regulated substances that can lead to serious health and safety concerns, especially when used outside of accredited research or therapeutic settings. This talk only represents the speaker's personal views and interpretation of ongoing research. This TEDx event was independently organized by volunteers by and for a youth audience. The guidelines we give TEDx organizers are described in more detail here: http://storage.ted.com/tedx/manuals/ ...

Core Viewpoint - Analog Devices, Inc. has appointed Dr. Yoky Matsuoka to its Board of Directors, expanding the board to 11 members, effective January 20, 2026 [1][2]. Group 1: Appointment Details - Dr. Matsuoka is an executive officer at Panasonic Holdings, responsible for global innovation and new business [2]. - She has held significant roles at major technology companies, including Vice President at Google’s healthcare organization and Chief Technology Officer at Google/Nest [2]. - Dr. Matsuoka has a strong academic background, having been an endowed professor at Carnegie Mellon University and the University of Washington, focusing on AI, robotics, and neuroscience [3]. Group 2: Contributions and Recognition - Dr. Matsuoka's expertise in integrating hardware, software, and AI aligns with Analog Devices' mission to deliver meaningful human outcomes [3]. - She received the MacArthur Genius Award for her contributions to robotics and neuroscience and founded the YokyWorks Foundation to assist children with physical and learning challenges [3][4]. - In 2023, she was recognized on Forbes' 50 Over 50: Innovation list and Inc.'s Top Female Founders list [4]. Group 3: Company Overview - Analog Devices, Inc. is a global leader in semiconductors, focusing on bridging the physical and digital worlds [5]. - The company reported revenue exceeding $11 billion in FY25, emphasizing its role in driving advancements across various sectors, including healthcare, energy, and automation [5].

Core Insights - Alkermes is positioned for growth in 2026, building on accomplishments from 2025 to enhance its value creation potential [3][5] - The company is characterized as a profitable neuroscience firm with a late-stage candidate, indicating a strong foundation for future development [5] Company Overview - Alkermes is participating in the 44th Annual Healthcare Conference, showcasing its management team and strategic direction [2] - The CEO, Richard Pops, expressed excitement about the company's trajectory and future opportunities [3] Financial and Strategic Position - The company emphasizes its strong foundation for both near-term and long-term growth, highlighting its profitability and leadership in the neuroscience sector [5]

Core Insights - AbbVie generates significant revenue from its immunology franchise, particularly from the strong uptake of its blockbuster drugs, Skyrizi and Rinvoq, which have helped the company achieve top-line growth despite the loss of exclusivity for Humira three years ago [1][8] - The company is expected to report Q4 and full-year 2025 results on February 4, 2025, with investors keenly awaiting sales figures for Skyrizi and Rinvoq [1] Immunology Performance - Skyrizi and Rinvoq have been successfully launched across major indications previously covered by Humira, including a new indication for atopic dermatitis, and have shown strong performance in the inflammatory bowel disease (IBD) market, particularly for ulcerative colitis (UC) and Crohn's disease (CD) [2] - Sales estimates for Q4 2025 are projected at $4.87 billion for Skyrizi and $2.33 billion for Rinvoq, driven by strong demand in the IBD market and new indications [3][8] Expansion into Other Therapeutic Areas - AbbVie is expanding its presence in neuroscience and oncology, with growth in neuroscience supported by the uptake of oral migraine therapies, Ubrelvy and Qulipta [4] - In oncology, AbbVie has broadened its portfolio to include solid tumors, led by newer assets such as Elahere and Emrelis [4] Competitive Landscape - The immunology market is highly competitive, with Johnson & Johnson (JNJ) as a key player, marketing blockbuster drugs Stelara and Tremfya, and focusing on Tremfya after Stelara lost U.S. patent exclusivity [5] - Eli Lilly (LLY) is also expanding its immunology presence with the FDA approval of Omvoh for UC, marking its first immunology drug approved for IBD in the U.S. [6] Financial Performance and Valuation - AbbVie shares have outperformed the industry year to date, trading at a P/E ratio of 15.50, which is lower than the industry average of 17.91 [7][9] - The bottom-line estimate per share for 2025 has slightly declined from $10.73 to $10.64, while estimates for 2026 have increased from $14.41 to $14.42 over the past 60 days [10]